Target intelligence / Profile preview

Sympathetic nerve fiber (pulmonary artery)

Molecular classification
Other
01

Overview

Sympathetic nerve fibers in the pulmonary artery are components of the pulmonary plexus, originating from the thoracic sympathetic ganglia, coursing with the vascular wall, and delivering adrenergic innervation. They regulate pulmonary arterial tone by releasing norepinephrine, causing vasoconstriction, and participate in physiological responses to stress. These nerve fibers have been investigated as potential targets for catheter-based denervation procedures, especially in the context of pulmonary arterial hypertension, where excessive sympathetic signaling is thought to contribute to high vascular resistance[1][2][5]. However, drug targeting is indirect and anatomical rather than molecular, making these fibers a target for interventional procedures rather than pharmacologic therapy. Note: - The entry does not represent a canonical molecule or receptor; it is an anatomical structure comprising neuronal tissue. - The correct canonical target would be a specific receptor (e.g., adrenergic receptor subtype) or enzyme in these nerve fibers, not the fibers themselves.

Other names
Sympathetic nervous innervation of pulmonary arteryPulmonary artery sympathetic nervesPulmonary plexus sympathetic fibers
02

Mechanism of action

Regional denervation (e.g., catheter-based ultrasound or radiofrequency ablation for PAH) attempts to disrupt sympathetic signaling to lessen vasoconstrictive tone

03

Biological functions

Vascular tone regulationVasoconstriction of pulmonary arteryModulation of blood pressure in pulmonary circulation
04

Disease associations

Pulmonary arterial hypertension (PAH), via abnormal sympathetic inputPossibly other forms of pulmonary circulation dysfunction (experimental)
05

Safety considerations

Risks of denervation procedures: incomplete ablation, unintended damage to adjacent structures, potential for altered vascular or cardiac function
06

Interacting drugs

Indirectly affected by sympatholytic agents (e.g., beta-blockers, but these act systemically or on receptors, not directly on the fibers)

1 more in the full profile.

07

Biomarkers

None (Innervation density or nerve marker staining such as tyrosine hydroxylase [TH] in research; not used for patient selection or monitoring)

Beyond the preview

Go deeper on Sympathetic nerve fiber (pulmonary artery).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sympathetic nerve fiber (pulmonary artery).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call